Estrella Immunopharma Shares Rise on Trial Update

The company reported no serious adverse events in the early stage of a trial testing its lymphoma therapy.

Updated on Oct. 22, 2026 in Biotech

Estrella Immunopharma Shares Rise on Trial Update

Live Poll

Is now a good time for you to invest in biotech stocks following positive clinical news?

Estrella Immunopharma reported that the first patient in the dose-expansion phase of its STARLIGHT-1 trial showed no serious adverse events one month after receiving EB103 infusions. The company also announced that previous high-dose escalation participants maintained a 100 percent complete response rate.

Why it matters

The update provides critical safety and efficacy data for Estrella Immunopharma's experimental lymphoma therapy, which uses the ARTEMIS platform to target refractory B-cell non-Hodgkin's lymphoma.

The therapy, EB103, utilizes ARTEMIS technology to deliver a dosage of 5 × 10⁶ T cells per kilogram. In the escalation phase, nine treated patients achieved a 100 percent complete response rate, with those lacking central nervous system involvement maintaining it for nine months.

The players

Estrella Immunopharma

A California-based biotechnology firm focused on developing clinical-stage therapies for oncology using proprietary T-cell engineering.

Eureka Therapeutics

A developer of T-cell immunotherapy platforms that licensed its ARTEMIS technology to Estrella Immunopharma for EB103 development.

The details

EB103 employs the ARTEMIS technology, a platform licensed from Eureka Therapeutics designed to improve T-cell safety and efficacy. In the dose-expansion phase, the patient received two infusions spaced three weeks apart to target B-cell non-Hodgkin's lymphoma. The absence of treatment-related serious adverse events in both the escalation and expansion phases suggests a manageable safety profile for the engineered cells.

October 21, 2026: Company released updated STARLIGHT-1 trial results.
October 21, 2026: Shares closed at $0.55 and rose to $0.65 after hours.
Past 12 months: Stock price declined by 76.39 percent.

The Tech Race

The STARLIGHT-1 trial marks a key development in the ongoing race to improve safety profiles for T-cell therapies in lymphoma patients. This update confirms the progression of the trial from the dose-escalation phase to the expansion cohort, refining the data needed for a pivotal strategy.

Investors saw share prices rise 37.50 percent during regular trading and a further 17.91 percent in after-hours movement following the announcement. For patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, this data signals continued clinical development of the EB103 experimental therapy.

The takeaway

The successful dosing of the first expansion-phase patient provides a preliminary safety marker to watch alongside the company's future pivotal trial plans. Stakeholders should track future trial updates to see if the 100 percent complete response rate persists in the larger expansion cohort.